Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study High levels of DNA replication stress and defects in the ...
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with ...
U.S. Fast Track designation underscores the strength of the alnodesertib clinical data generated to date and the high degree of unmet need in 3L mCRC CAMBRIDGE, United Kingdom and NEW YORK, September ...
A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ATM ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported data highlighting ...
A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ATM ...
I. Platinum-based therapies induce DNA inter-strand crosslinks (ICLs), which exacerbate genomic instability and impede DNA replication. In BRCA1/2-deficient tumor cells, the repair of these DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results